>[ALNY] …but note that it is for data in primates, not rodents, which it implies it is very close to clinical trials.<
The PR says clinical trials are 18-24 months away.
One immediate question I have about the results described in the PR: mRNA expression for the protein in question (apoB) was reduced by 90% and the serum level of the protein was reduced by 75% -- why the discrepancy between the 90% and 75% figures?
A second question (raised on the NSTK ymb) is whether getting siRNAs into the liver, specifically, means that ALNY has attained true systemic delivery. Apropos to this second question is this remark from NSTK’s CSO on NTSK’s 2/23/06 CC:
>>
Other companies describe systemic delivery of siRNAs specifically targeting the liver or spleen. However, the physicians in the audience will realize that the liver and spleen are the scavenger organs of the body. So to say that an siRNA is directed at liver and spleen might be the same as saying that the siRNA is simply being eliminated by the body.
<<
Comments?
Market Data 
Markets 
AI
